{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:50:31Z","timestamp":1790895031916,"version":"4.1.0"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,12,6]],"date-time":"2005-12-06T00:00:00Z","timestamp":1133827200000},"content-version":"vor","delay-in-days":8375,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[1983,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lassa virus\u2010immune plasma has been used to treat human Lassa fever patients; however, criteria for plasma selection were based arbitrarily on available serologic tools and protective efficacy was never directly assessed. To test the validity of plasma therapy for Lassa virus infections in an animal model, and to develop biologically relevant criteria for selection of protective immune plasma, inbred, strain 13 guinea pigs were infected with a lethal dose of Lassa virus and treated with various Lassa\u2010immune plasmas obtained from guinea pigs, primates, and convalescent human patients. Neutralizing antibody titers were determined in a virus dilution, plaque reduction test, and were expressed as a log<jats:sub>10<\/jats:sub> plaque\u2010forming units (PFU) neutralization index (LNI). All guinea pigs treated with immune plasma 6 ml\/kg\/treatment on days 0, 3, and 6 after virus inoculation were protected, provided the LNI exceeded 2.0. Plasmas obtained from donors in early convalescence (32\u201345 days) had low titers of N\u2010antibody (LNI &lt; 2) and failed to confer protection, despite high titers of Lassa antibody measured in the indirect fluorescent antibody (IFA) test. Higher doses of marginally titered plasma conferred increased protection. The degree of protection and suppression of viremia was closely associated with LNI and not IFA titers. Administration of low\u2010titered plasma did not result in immune enhancement. A high dose of human plasma from Liberia (12 ml\/kg\/treatment) was required to confer complete protection to guinea pigs infected with a Lassa virus strain from Sierra Leone (LNI = 1.6), while a lower dose (3 ml\/kg\/treatment) was sufficient for protection against a Liberian strain (LNI = 2.8), suggesting that a geographic matching of immune plasma and Lassa virus strain origin may increase treatment success. These studies support the concept of plasma therapy for Lassa infection and suggest that the plaque reduction neutralization test is more appropriate than the IFA test for predicting protective efficacy of passively administered plasma.<\/jats:p>","DOI":"10.1002\/jmv.1890120203","type":"journal-article","created":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T11:40:14Z","timestamp":1172835614000},"page":"93-102","source":"Crossref","is-referenced-by-count":71,"title":["Protection of lassa virus\u2010infected guinea pigs with lassa\u2010immune plasma of guinea pig, primate, and human origin"],"prefix":"10.1002","volume":"12","author":[{"given":"P. B.","family":"Jahrling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,12,6]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"435","article-title":"Lassa immune serum","volume":"5","author":"Clayton AJ","year":"1977","journal-title":"Bulletin of the World Health Organization"},{"key":"e_1_2_1_3_1","unstructured":"CondieRM(1979a): Preparation and intravenous use of undenatured human IgG. InAlvingBM FinlaysonJS(eds): \u201cImmunoglobulins: Characteristics and Uses of Intravenous Preparations.\u201d Washington: DHSS Publication No. (FDA)\u201080\u20109005 pp179\u2013193."},{"key":"e_1_2_1_4_1","first-page":"66","article-title":"Treatment of life\u2010threatening infections in renal transplant recipients with high\u2010dose intravenous human IgG","volume":"11","author":"Condie RM","year":"1979","journal-title":"Transplantation Proceedings"},{"key":"e_1_2_1_5_1","first-page":"723","article-title":"Protection of monkeys against Machupo virus by the passive administration of Bolivian haemorrhagic fever immunoglobulin (human origin)","volume":"52","author":"Eddy GA","year":"1975","journal-title":"Bulletin of the World Health Organization"},{"key":"e_1_2_1_6_1","first-page":"884","volume-title":"Manual of Clinical Microbiology","author":"Jahrling PB","year":"1980"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/141.5.580"},{"key":"e_1_2_1_8_1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1128\/iai.37.2.771-778.1982","article-title":"Pathogenesis of Lassa virus infection in guinea pigs","volume":"37","author":"Jahrling PB","year":"1982","journal-title":"Infection and Immunity"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6073.1399"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.7883\/yoken1952.25.309"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1970.19.677"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)92335-3"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1974.23.1140"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-142-37060"},{"key":"e_1_2_1_15_1","first-page":"429","article-title":"Indirect immunofluorescence for the diagnosis of Lassa fever infection","volume":"52","author":"Wulff H","year":"1975","journal-title":"Bulletin of the World Health Organization"},{"key":"e_1_2_1_16_1","first-page":"631","article-title":"Immunoglobulin M and G responses measured by immunofluorescence in patients with Lassa or Marburg virus infections","volume":"57","author":"Wulff H","year":"1979","journal-title":"Bulletin of the World Health Organization"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.1890120203","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.1890120203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T21:45:46Z","timestamp":1697751946000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.1890120203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,1]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1983,1]]}},"alternative-id":["10.1002\/jmv.1890120203"],"URL":"https:\/\/doi.org\/10.1002\/jmv.1890120203","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,1]]}}}